Akari Therapeutics (AKTX) Competitors $0.93 -0.09 (-8.82%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$0.92 -0.01 (-0.54%) As of 10/10/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. SRZN, ALXO, ZNTL, SPRO, CGTX, ADVM, IRD, STTK, MGNX, and VTGNShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Surrozen (SRZN), ALX Oncology (ALXO), Zentalis Pharmaceuticals (ZNTL), Spero Therapeutics (SPRO), Cognition Therapeutics (CGTX), Adverum Biotechnologies (ADVM), Opus Genetics (IRD), Shattuck Labs (STTK), MacroGenics (MGNX), and VistaGen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Surrozen ALX Oncology Zentalis Pharmaceuticals Spero Therapeutics Cognition Therapeutics Adverum Biotechnologies Opus Genetics Shattuck Labs MacroGenics VistaGen Therapeutics Surrozen (NASDAQ:SRZN) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings. Which has more volatility and risk, SRZN or AKTX? Surrozen has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Does the media refer more to SRZN or AKTX? In the previous week, Surrozen and Surrozen both had 4 articles in the media. Surrozen's average media sentiment score of 0.62 beat Akari Therapeutics' score of 0.48 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in SRZN or AKTX? 66.6% of Surrozen shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 45.2% of Surrozen shares are owned by insiders. Comparatively, 38.1% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend SRZN or AKTX? Surrozen currently has a consensus target price of $38.50, indicating a potential upside of 181.54%. Akari Therapeutics has a consensus target price of $3.30, indicating a potential upside of 254.84%. Given Akari Therapeutics' higher probable upside, analysts clearly believe Akari Therapeutics is more favorable than Surrozen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is SRZN or AKTX more profitable? Akari Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -274.42%. Akari Therapeutics' return on equity of -78.03% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets Surrozen-274.42% -545.43% -64.40% Akari Therapeutics N/A -78.03%-31.62% Which has stronger earnings & valuation, SRZN or AKTX? Akari Therapeutics has lower revenue, but higher earnings than Surrozen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurrozen$10.65M11.00-$63.56M-$14.42-0.95Akari TherapeuticsN/AN/A-$19.79MN/AN/A SummarySurrozen and Akari Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.27M$3.38B$6.12B$10.63BDividend YieldN/A2.29%5.67%4.71%P/E RatioN/A22.2585.9726.57Price / SalesN/A461.00612.53132.55Price / CashN/A47.2238.5062.09Price / Book1.1110.2112.756.53Net Income-$19.79M-$52.40M$3.31B$276.43M7 Day Performance1.53%0.86%0.80%-0.88%1 Month Performance20.78%10.39%6.21%3.55%1 Year Performance-65.56%27.24%80.34%37.91% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics2.613 of 5 stars$0.93-8.8%$3.30+254.8%-64.8%$33.27MN/A0.009News CoverageAnalyst ForecastGap DownSRZNSurrozen2.1733 of 5 stars$13.84+1.1%$38.50+178.2%+21.7%$117.29M$10.65M-0.9680News CoverageAnalyst ForecastHigh Trading VolumeALXOALX Oncology3.7518 of 5 stars$2.11-3.2%$3.30+56.4%+13.9%$116.74MN/A-0.9640Analyst ForecastZNTLZentalis Pharmaceuticals1.7127 of 5 stars$1.59-1.2%$5.84+267.3%-42.9%$116.14M$67.43M-0.70160Analyst ForecastSPROSpero Therapeutics4.4253 of 5 stars$2.09+2.0%$5.00+139.2%+81.5%$115.36M$34.09M-2.13150News CoverageAnalyst ForecastCGTXCognition Therapeutics2.7103 of 5 stars$1.54-0.6%$2.83+84.0%+347.1%$113.96MN/A-2.3020News CoveragePositive NewsAnalyst ForecastADVMAdverum Biotechnologies3.7543 of 5 stars$5.30-1.7%$19.75+272.6%-35.3%$113.11M$1M-0.68190Analyst ForecastIRDOpus Genetics2.307 of 5 stars$2.02+7.4%$7.33+263.0%N/A$112.63M$15.42M-1.0514Analyst ForecastGap UpHigh Trading VolumeSTTKShattuck Labs3.8338 of 5 stars$2.59+10.2%$3.00+15.8%+25.2%$112.57M$5.72M-2.14100Analyst ForecastMGNXMacroGenics4.3872 of 5 stars$1.76-1.1%$3.60+104.5%-54.8%$112.51M$149.96M-3.09430News CoverageAnalyst ForecastVTGNVistaGen Therapeutics1.0338 of 5 stars$3.89+6.6%N/A+33.4%$111.98M$646K-2.1940News CoverageAnalyst Forecast Related Companies and Tools Related Companies Surrozen Competitors ALX Oncology Competitors Zentalis Pharmaceuticals Competitors Spero Therapeutics Competitors Cognition Therapeutics Competitors Adverum Biotechnologies Competitors Opus Genetics Competitors Shattuck Labs Competitors MacroGenics Competitors VistaGen Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
